Kim J J, Baek M J, Kim L, Kim N G, Lee Y C, Song S Y, Noh S H, Kim H
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Lab Invest. 1999 Sep;79(9):1113-20.
Microsatellite instability (MSI) and frameshift mutations in genes containing nucleotide repeats have been reported in a subset of gastric carcinomas, but the mutational profiles in precancerous lesions have not been characterized. To characterize the genetic events during gastric carcinogenesis, we analyzed DNA from 56 gastric adenomas and 167 gastric carcinomas for MSI using five microsatellite markers and for frameshift mutations at coding nucleotide repeats of the type II transforming growth factor beta receptor, BAX, hMSH3, hMSH6, IGF II receptor, and E2F-4 genes. On the basis of the number of markers displaying instability per tumor, the tumors were divided into three groups: those with two or more of the five markers showing instability (high MSI [MSI-H]), those with one of the five markers showing instability (low MSI [MSI-L]), and those with no instability. MSI-H was found in 8 adenomas (14%) and 19 carcinomas (11%), and MSI-L was found in 8 adenomas (14%) and 9 carcinomas (5%). These groups were tested for correlations with several clinicopathologic parameters. MSI-H gastric adenomas were related to the high histologic grade of composing dysplastic glands (p = 0.004), and MSI-H gastric carcinomas were associated with exophytic tumor growth (p = 0.005). We found 48 frameshift mutations at coding nucleotide repeats of the six genes, and all mutations except one were found in MSI-H gastric tumors. Only one of the 17 MSI-L tumors showed frameshift mutations at coding nucleotide repeats of the transforming growth factor beta receptor II gene. Compared with MSI-H gastric carcinomas, MSI-H adenomas had no mutations in the hMSH6 and the IGF II receptor genes, less frequent mutations in the transforming growth factor beta receptor II (38% versus 63%), BAX (13% versus 37%), and hMSH3 (13% versus 37%) genes, and more frequent mutations in the E2F-4 (50% versus 37%) gene. Our findings suggest that MSI and E2F-4 mutations are early genetic events and that mutations of the other five genes are accumulated during the progression of gastric carcinomas with MSI.
在一部分胃癌中已报道存在微卫星不稳定性(MSI)以及含核苷酸重复序列基因中的移码突变,但癌前病变中的突变谱尚未明确。为了明确胃癌发生过程中的遗传事件,我们使用五个微卫星标记分析了56例胃腺瘤和167例胃癌的DNA以检测MSI,并检测了II型转化生长因子β受体、BAX、hMSH3、hMSH6、IGF II受体和E2F-4基因编码核苷酸重复序列处的移码突变。根据每个肿瘤显示不稳定性的标记数量,将肿瘤分为三组:五个标记中有两个或更多显示不稳定性的肿瘤(高MSI [MSI-H])、五个标记中有一个显示不稳定性的肿瘤(低MSI [MSI-L])以及无不稳定性的肿瘤。在8例腺瘤(14%)和19例癌(11%)中发现了MSI-H,在8例腺瘤(14%)和9例癌(5%)中发现了MSI-L。对这些组进行了与几个临床病理参数的相关性检测。MSI-H胃腺瘤与构成发育异常腺体的高组织学分级相关(p = 0.004),MSI-H胃癌与外生性肿瘤生长相关(p = 0.005)。我们在六个基因的编码核苷酸重复序列处发现了48个移码突变,除一个突变外,所有突变均在MSI-H胃肿瘤中发现。在17例MSI-L肿瘤中,只有1例在转化生长因子β受体II基因的编码核苷酸重复序列处显示移码突变。与MSI-H胃癌相比,MSI-H腺瘤在hMSH6和IGF II受体基因中无突变,在转化生长因子β受体II(38%对63%)、BAX(13%对37%)和hMSH3(13%对37%)基因中的突变频率较低,而在E2F-4(50%对37%)基因中的突变频率较高。我们的研究结果表明,MSI和E2F-4突变是早期遗传事件,而其他五个基因的突变是在MSI胃癌进展过程中积累的。